Defining and Modulating BRCAness to Improve the Precision of Prostate Cancer Therapy

reportActive / Technical Report | Accesssion Number: AD1194712 | Open PDF

Abstract:

This proposal is focused on exploiting a specific subtype of metastatic CRPC, termed Homology Directed DNA Repair Deficient (HDR-D) prostate cancer (PC) to enhance treatment outcomes, reduce morbidity and improve survival. HDR-D represents at least 20% of metastatic PC and is most commonly identified through the genomic analysis of biopsies from metastatic tumors and identifying mutations in BRCA1, BRCA2 and related genes.

Author(s):
Nelson, Peter S
Author Organization(s):
FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA
Funding Organization(s):
ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND FORT DETRICK MD, FORT DETRICK , MD
Document Type:
Technical Report/Annual Report
Publication Date:
2022 Aug 01
Pagination:
48

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution Code:
A - Approved For Public Release
Distribution Statement: Public Release

RECORD

Collection: TRECMS
Identifying Numbers
Grant Number(s):
W81XWH-21-1-0264, PC200262
Subject Terms
Communities of Interest:
No COI(s) Identified
Descriptor(s):
medical personnel, cell physiological processes, data science, body weight, detection, personnel management, whole genome sequencing, accuracy, acquisition, androgen receptors, cell line, drug combinations, organizational structure, statistics, biospecimens, cancer, carcinoma
Keyword(s):
castrate-resistant prostate cancer, DNA repair, homology-directed DNA repair deficiency, PARP inhibitor
Subject Categories:
Biological and Medical Sciences; Biological and Medical Sciences
Creation Date:
2023 Mar 06
Update Date:
2023 May 16